Ashwani Verma
UBS Investment Bank, Research Division

Great. Good day, everybody. My name is Ash Verma. I cover SMID-Cap Biotech and Spec Pharma at UBS and really excited to have Dianthus’ Marino Garcia, who’s the CEO. Thank you so much for joining us. Very excited to learn more about Dianthus today. I know you have some slides that you want to run through, and then we can get into some Q&A.

Marino Garcia
President, CEO & Director

Thank you, Ash, and thank you to UBS for this opportunity to update everyone on all the exciting developments at Dianthus Therapeutics. I’ll just take a few moments for — to set the stage, and then we can jump into the questions. Just obviously, I’ll be making some forward-looking statements. I just refer everyone to our website and our SEC filings for all the appropriate risks around Dianthus and investing in the company.

Before I jump into our lead program and set the stage for claseprubart, Dianthus, what we’re trying to do is build a very exciting autoimmune-focused biotech company. We have 3 programs. Our lead program, claseprubart, is a highly potent extended half-life active C1s inhibitor that inhibits only the classical pathway, leaving the lectin and alternative pathways intact. We’ll talk a little bit about what that means in terms of its differentiation.

Our second program is DNTH212. It’s a bifunctional fusion protein that we in-licensed from China last year. On one side, it’s a BDCA2 inhibitor that has demonstrated superior pDC depletion when compared to litifilimab, which is in Biogen’s portfolio, and we’ll be reading out two Phase III

Share.
Exit mobile version